A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

01 Pubblicazione su rivista
Gamucci Teresa, Pizzuti Laura, Natoli Clara, Mentuccia Lucia, Sperduti Isabella, Barba Maddalena, Sergi Domenico, Iezzi Laura, Maugeri-Saccà Marcello, Vaccaro Angela, Magnolfi Emanuela, Gelibter Alain, Barchiesi Giacomo, Magri Valentina, D'Onofrio Loretta, Cassano Alessandra, Rossi Ernesto, Botticelli Andrea, Moscetti Luca, Omarini Claudia, Fabbri Maria Agnese, Scinto Angelo Fedele, Corsi Domenico, Carbognin Luisa, Mazzotta Marco, Bria Emilio, Foglietta Jennifer, Samaritani Riccardo, Garufi Carlo, Mariani Luciano, Barni Sandro, Mirabelli Rosanna, Sarmiento Roberta, Graziano Vincenzo, Santini Daniele, Marchetti Paolo, Tonini Giuseppe, Di Lauro Luigi, Sanguineti Giuseppe, Paoletti Giancarlo, Tomao Silverio, De Maria Ruggero, Veltri Enzo, Paris Ida, Giotta Francesco, Latorre Agnese, Giordano Antonio, Ciliberto Gennaro, Vici Patrizia
ISSN: 1538-4047

We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test. Median follow-up, length of pertuzumab/trastuzumab/taxane treatment and of pertuzumab, trastuzumab maintenance were 21, 4 and 15 months, respectively. The response rate was 77.3%, and the clinical benefit rate 93.6%. Median progression-free survival (mPFS) was 21 months, and median overall survival (mOS) was not reached. When comparing patients by trastuzumab-pretreatment, similar PFS were observed, although a longer OS was reached in trastuzumab-naïve patients (p = 0.02). Brain metastases at baseline and their development in course of therapy were associated with significantly shorter PFS (p = 0.0006) and shorter OS, although at a not fully statistically relevant extent (p = 0.06). The addition of maintenance endocrine therapy (ET) to pertuzumab/trastuzumab maintenance was associated with longer PFS (p = 0.0001), although no significant differences were detected in OS (p = 0.31). Results were confirmed by propensity score analysis (p = 0.003 and p = 0.46, respectively). In multivariate models, longer PFS was related to lower Performance Status (PS) (p = 0.07), metastatic stage at diagnosis (p = 0.006) and single metastatic site (p < 0.0001). An OS advantage was observed with lower PS (p < 0.0001), single metastatic site (p = 0.004), no prior exposure to trastuzumab (p = 0.004) and response to pertuzumab-based treatment (p = 0.003). Our results confirm that trastuzumab/pertuzumab/taxane is the standard of care as first-line treatment of patients with HER2-positive ABC even in the real-world setting. Moreover, the double-maintenance therapy (HER2 block and ET) is strongly recommended when feasible.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma